The French Society of Cardiology particularly underscores three key aspects:
Addressing Supply Shortages
In electrophysiology, rare metals and minerals essential for device manufacturing are often procured from regions facing geopolitical issues. Recognizing this aspect is crucial in global production and demand forecasts. Moreover, competing original manufacturers frequently share suppliers, heightening the risk of shortages. Recent years have seen evidence of this vulnerability, with semiconductor shortages causing disruptions in multiple medical device production lines. Additionally, the Covid-19 pandemic has led to delays.
Environmental Protection
Not only are supply chains at risk, but the raw materials are also costly, both financially and environmentally. For instance, catheters crafted from precious materials like gold, platinum, or complex polymers contribute significantly (40%) to the ecological footprint of atrial fibrillation ablation procedures.
Cost Reduction
Although remanufacturing practices are currently prohibited in France, the group notes that numerous medical specialty societies endorse this approach. Beyond the aforementioned aspects, it also offers economic viability. The position paper aims to “raise awareness among physicians and demonstrate solutions for improvement.” Consequently, the group of authors underscores the safety of Medical Remanufacturing and highlights that both the US Food and Drug Administration (FDA) and the European Union, through its Medical Device Regulation (MDR), expressly permit the reprocessing of single-use products and have established stringent rules for it.
Expanding on this, the authors critique the inconsistent regulations in Europe, which have resulted in the procedure not being permitted in all EU member states. Furthermore, they call upon original manufacturers to take the lead in reprocessing. The stance of the specialty society unequivocally supports the reprocessing practice, and anticipation surrounds the implications that will emerge in France.
